Kalvista Pharmaceuticals, Inc. · NASDAQ:KALV
Kalvista Pharmaceuticals — Investor Presentation (January 2026)
20 slides from Kalvista Pharmaceuticals's investor presentation, Jan 8, 2026
Slide 1: KalVista Pharmaceuticals Corporate Overview January 2026
KalVista Pharmaceuticals Corporate Overview January 2026 Exhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of histor
Slide 3: We deliver novel therapies that empower people to live better lives
We deliver novel therapies that empower people to live better lives We aim to develop therapies that change the treatment landscape for rare diseases with high unmet needs—beginning with hereditary angioedema (HAE).
Slide 4: KalVista: A patient-focused rare disease company
KalVista: A patient-focused rare disease company We are a global pharmaceutical company that developed and is commercializing EKTERLY as the first and only oral on-demand therapy for HAE in the U.S. and other key global markets. Our strategy is to leverage the global capabilities and infrastructure
Slide 5: Our flagship product: EKTERLY
Our flagship product: EKTERLY Please see Prescribing Information at KalVista.com Poised to become the foundational therapy for hereditary angioedema (HAE) Approved in seven key global markets: US, EU, UK, Switzerland, Australia, Japan and Singapore Indicated for the treatment of acute attacks of HAE
Slide 6: HAE Unmet Need & EKTERLY Clinical Data
HAE Unmet Need & EKTERLY Clinical Data
Slide 7: The significant burden of HAE: unpredictable swelling attacks
The significant burden of HAE: a rare disease defined by unpredictable swelling attacks 1 in 35,000 - 1 in 50,000 people worldwide1,2 Lifelong attacks of debilitating swelling in the face, extremities, abdomen and genitals2 Life-threatening if the upper airway is involved3 Attack severity may incr
Slide 8: Treatment guidelines list four key recommendations for treatment of HAE attacks
Treatment guidelines list four key recommendations for treatment of HAE attacks1-3 Treat attacks as early as possible after recognition of onset Treatment should be considered for all attacks, regardless of anatomic location or severity Train all patients in the self-administration of on-demand trea
Slide 9: Management of HAE prior to EKTERLY
Management of HAE prior to EKTERLY Long-term prophylaxis in majority of patients Injectable or intravenous on-demand On-demand treatment is underutilized Complex logistics and painful Delays and denial of treatment Inadequate control High treatment burden High cost Less benefit than anticipated in m
Slide 10: Management of HAE with EKTERLY
Management of HAE with EKTERLY 1. Busse PJ, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. 2. Maurer M, et al. Allergy. 2022;77(7):1961-1990. Long-term prophylaxis in appropriate patients1,2 EKTERLY On-Demand Treatment First and only oral on-demand HAE treatment Poised to Become the Foun
Slide 11: The largest clinical data set generated in HAE
1. NCT05505916, EudraCT: 2021-001176-42. Note: Data cutoff date of September 14, 2024. 2. Reidl MA, et al. Presented at WSAAI Annual Meeting; Feb. 9-13, 2025, Manning ME, et al. Presented at WSAAI Annual Meeting; Feb. 9-13, 2025. 3. Lumry WR, et al. Presented at C1-INH Workshop; May 29-June 1, 2025
Slide 12: Pediatrics expansion expected to yield a complete family solution
Pediatrics expansion expected to yield a complete family solution 1Company data on file 2Aygoren-Pursun, et al. Sebetralstat for On-Demand Treatment of HAE in Pediatric (2-11y) Patients” Interim Results from KONFIDENT-KID Presented at ACAAI Annual Scientific Meeting; November 6-10, Orlando, FL. Popu
Slide 13: EKTERLY Commercial Strategy & Launch
EKTERLY Commercial Strategy & Launch
Slide 14: EKTERLY: Redefining on-demand treatment for HAE
EKTERLY: Redefining on-demand treatment for HAE An oral option that enables early treatment across all attack types Early Treatment Injectable-like Efficacy All Attacks Effective against all types of HAE attacks, regardless of location, severity, or use of prophylactic therapy Proven to halt attack
Slide 15: Performance Since Launch
Performance Since Launch1 ~$49M 1,318 580 Leveraging strong 2025 US launch momentum to accelerate adoption of EKTERLY Refills account for >50% of Q4 revenue 85% of Tier 1 accounts have prescribed EKTERLY 74% of start forms are from repeat prescribers July 7, 2025 – December 31, 2025; 2. Percentage b
Slide 16: EKTERLY could fundamentally reshape the US market
Sources: Evaluate Pharma and Company Reports. Forward-looking statements represented on this slide are subject to inherent uncertainties that could cause actual results to differ and such differences could be material. Please refer to the Company’s Cautionary Statements $650M Current U.S. Market Dri
Slide 17: EKTERLY poised for rapid global expansion
2025 2026 Launched in the US Launched in Germany European launches Japan launch Canada, LATAM and rest of world launches EKTERLY poised for rapid global expansion global regulatory approvals: US, EU, UK, Switzerland, Australia, Japan and Singapore commercial partnerships: Canada, Japan and Latin Ame
Slide 18: Internal Pipeline: Oral FXIIa Inhibitor
Internal Pipeline: Oral FXIIa Inhibitor Future growth strategy Assessing internal and external opportunities for future pipeline expansion Portfolio of FXIIa inhibitor compounds with potential for clinical development à Potential indications in anti-thrombotic and inflammatory categories à Will eval
Slide 19: Strong Position, Clear Growth Trajectory
Strong Position, Clear Growth Trajectory Built on five differentiated value drivers Global Opportunity Rare Disease Expertise Financial Foundation Protected Value Growth Strategy EKTERLY approved in 7 key markets; launched in the US & Germany; commercial partners in place in Canada, Japan & Latin Am
Slide 20: Nasdaq: KALV
Nasdaq: KALV
KalVista Pharmaceuticals — Investor Presentation (January 2026) on 6ix